Oxford Genetics Ltd

Genetic engineering (GE) is an established tool for R&D and promises to become a globally used approach to correct and treat important diseases, such as cancer and genetic disease, and also able to tackle and solve important environmental issues. Current approaches are dependent upon manual labour and extensive screening, and are highly inefficient and ti...

Many modern therapeutic treatments require products and drugs that must to be manufactured in human cells for them to work effectively. At present, the human cell based manufacturing industry is dominated by a few standard systems (normally CHO or HEK-293). These systems were first established for research use only, in some cases as far back as 1957 (CHO)...

Antibodies are one the most successful treatments for a range of human diseases, including virus and bacterial infections and cancer. They work by binding to other molecules, thereby inactivating them or allow the immune system to clear them from the blood. However, the isolation of antibodies that recognise a specific target remains challenging, signific...

Recent advances in the treatment of a range of autoimmune diseases and cancer have required increasingly complex medical solutions. One rapidly expanding range of very successful treatments is the delivery of DNA to human cells (gene therapy) to provide them with new features and properties to help fight disease. A highly efficient method of achieving thi...

Awaiting Public Project Summary

Many different factors influence whether a piece of DNA will work in a biological setting, to express the protein it encodes. Proteins represent a broad new class of exciting but expensive new medicines. Poor DNA activity is particularly problematic when manufacturers of proteins need to produce large quantities by industrial manufacture. At Oxford Geneti...

The production of recombinant proteins for medical research and healthcare is a rapidly expanding area of biotechnology. However, many of these proteins must be manufactured in expensive mammalian systems to ensure correct protein folding, where the yield is typically low in comparison to bacterial systems (usually 100-1000-fold lower). In part this is du...

Oxford Genetics is a new biotechnology company that aims to become the UK’s pre-eminent producer of genes and DNA plasmids. The company has been trading for just under one year, and has already established a worldwide market for our DNA products. Genes encode proteins, and in this project we will develop a technology that can ensure the genes customers bu...

The production of recombinant proteins for medical research and healthcare is a rapidly expanding area of biotechnology. However, many of these proteins must be manufactured in expensive mammalian systems to ensure correct protein folding, where the yield is typically low in comparison to bacterial systems (usually 100-1000-fold lower). In part this is du...

Modern biological and medical research is highly dependent on genetic engineering (i.e. the modification of Deoxyribose Nucleic Acid, DNA). DNA is the molecule that encodes all of the genes which make an individual organism. Its modification has revolutionised biomedical research, particularly in the fields of vaccinology, oncology, immunology and microbi...